Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Increase in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 8,170,000 shares, a growth of 23.4% from the March 31st total of 6,620,000 shares. Based on an average daily volume of 1,610,000 shares, the short-interest ratio is presently 5.1 days. Approximately 9.3% of the shares of the stock are sold short.

Insider Buying and Selling

In other Compass Therapeutics news, Director Carl L. Gordon sold 3,571,428 shares of the firm’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Anderman purchased 20,000 shares of the business’s stock in a transaction dated Monday, April 7th. The stock was bought at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now owns 21,000 shares of the company’s stock, valued at approximately $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 28.50% of the company’s stock.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors have recently bought and sold shares of the business. Rhumbline Advisers lifted its holdings in shares of Compass Therapeutics by 3.1% during the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock valued at $187,000 after acquiring an additional 3,822 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Compass Therapeutics by 11.3% in the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock valued at $57,000 after purchasing an additional 4,018 shares during the period. Bank of New York Mellon Corp grew its holdings in Compass Therapeutics by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company’s stock valued at $463,000 after purchasing an additional 5,590 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Compass Therapeutics by 31.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock worth $69,000 after acquiring an additional 11,326 shares in the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Stock Up 3.8 %

CMPX stock opened at $1.89 on Friday. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08. The company has a market cap of $261.35 million, a price-to-earnings ratio of -5.11 and a beta of 1.40. The business has a fifty day simple moving average of $2.10 and a 200-day simple moving average of $2.10.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

CMPX has been the subject of a number of analyst reports. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 target price on shares of Compass Therapeutics in a research note on Monday, April 21st. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Finally, Piper Sandler started coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Compass Therapeutics presently has a consensus rating of “Buy” and an average price target of $13.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.